Literature DB >> 3178158

Serum levels of CA-50, CA-19.9, CA-125, CA-15.3, enolase and carcino-embryonic antigen in non neoplastic diseases of the lung.

F Marechal1, G Berthiot, G Deltour.   

Abstract

There is not as yet a specific marker for lung cancer. We tested the specificity of six serum markers using radio-immunological assays (CA-50, CA-19.9, CA-125, CA-15.3, Enolase, CEA) in 60 patients with non-neoplastic diseases of the lung (COPD: 28 patients, acute pneumonia: 23 patients, allery: 9 patients). No correlation was found between the percentage of false positivities on the one hand, and sex, age and smoking habits on the other. CA-125 proved to be positive in 74% of acute pneumonia cases. The rate of false positive values is low with CEA (3.3%), Enolase (6.7%) and CA-15.3 (5%) and therefore the cut-off value we chose for these markers was adequate. This is not the case with CA-50, CA-19.9 and CA-125, for which we observed a high rate of false positive values (33.3%, 13.3% and 53.3% respectively) and for which higher cut-off values must be adopted.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3178158

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  False-positive findings for tumor markers after curative gastrectomy for gastric cancer.

Authors:  Takao Ohtsuka; Seiji Sato; Yoshihiko Kitajima; Masayuki Tanaka; Yuji Nakafusa; Kohji Miyazaki
Journal:  Dig Dis Sci       Date:  2007-05-03       Impact factor: 3.199

2.  Different roles of tumor marker monitoring after curative resections of gastric and colorectal cancers.

Authors:  Takao Ohtsuka; Yuji Nakafusa; Seiji Sato; Yoshihiko Kitajima; Masayuki Tanaka; Kohji Miyazaki
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

3.  Granulation Tissue-induced Pseudo-relapse During Nivolumab Treatment in Advanced Non-small Cell Lung Cancer.

Authors:  Chihiro Ando; Eiki Ichihara; Hirohisa Kano; Yoshitaka Iwamoto; Atsuko Hirabae; Takamasa Nakasuka; Yoshinobu Maeda; Katsuyuki Kiura
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.